Cangrelor During Percutaneous Coronary Intervention in Patients With Cardiogenic Shock or Cardiac Arrest
For patients with cardiogenic shock, administration of cangrelor during PCI was associated with a lower risk for both MACE and all-cause mortality. For patients with cardiac arrest, no such benefit was observed, and a higher risk for major bleeding was found.
Authors
- Oskar Love Emilsson (ORCID: https://orcid.org/0000-0001-8777-7397)
- Jonas Persson (ORCID: https://orcid.org/0000-0001-6722-8745)
- David Erlinge (ORCID: https://orcid.org/0000-0003-3042-5766)
- Per Grimfjärd (ORCID: https://orcid.org/0000-0002-7231-715X)
- Moman A. Mohammad (ORCID: https://orcid.org/0000-0003-4242-9801)
- Irene Santos‐Pardo (ORCID: https://orcid.org/0000-0002-5933-7295)
- Sasha M. Koul (ORCID: https://orcid.org/0009-0009-8408-8698)
Institutions
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Lund University (SE)
- Karolinska Institutet (SE)
- Stockholm South General Hospital (SE)
- Skåne University Hospital (SE)
Publication Details
- Journal
- JACC: Cardiovascular Interventions
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.jcin.2025.01.451
- Citations
- 9
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 12.49
Funders
- Skånes universitetssjukhus